KAS
WVE icon

Kemnay Advisory Services’s Wave Life Sciences WVE Stock Holding History

Kemnay Advisory Services’s Portfolio WVE Stock Details WVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,201
Closed -$8.71K – 1369
2026
Q1 		$8.71K Buy
+1,201
New +$15.6K ﹤0.01% 1034

Other funds holding WVE

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GP
GSK plc London $602M AUM
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RAM
Readystate Asset Management Chicago, Illinois $2.93B AUM 18.57% 1-Year Est. Return

Kemnay Advisory Services's WVE Position: Q2 2026 in Review

Kemnay Advisory Services sold out of Wave Life Sciences (WVE) in Q2 2026, closing a stake of 1,201 shares — an estimated $8.71K sold.

Kemnay Advisory Services first reported a position in WVE in Q1 2026 and held it in 1 quarter. The position peaked at $8.71K in Q1 2026. 239 funds tracked by Wall St. Rank hold WVE as of Q2 2026.

  • Kemnay Advisory Services reported no remaining Wave Life Sciences position as of Q2 2026 after selling out during the quarter.
  • Kemnay Advisory Services sold 1,201 Wave Life Sciences shares in Q2 2026, an estimated $8.71K.
  • Kemnay Advisory Services first reported a position in Wave Life Sciences in Q1 2026 and held it in 1 quarter.
  • Kemnay Advisory Services's Wave Life Sciences position peaked at $8.71K in Q1 2026.
  • 239 funds tracked by Wall St. Rank held Wave Life Sciences as of Q2 2026.

Based on Kemnay Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.